Why Parkinson's disease trial monitoring matters
Parkinson's disease is one of the most active areas in neurology drug development, with hundreds of active trials on ClinicalTrials.gov spanning disease modification, symptomatic relief, and emerging modalities including gene therapy and cell-based approaches. The pipeline has accelerated significantly as alpha-synuclein biology, LRRK2 inhibition, and GBA1 pathways have matured as targets.
Key signals that Parkinson's professionals track:
- New neuroprotective and disease-modifying programs targeting alpha-synuclein aggregation, LRRK2 inhibition, and mitochondrial dysfunction
- GBA1-positive patient subpopulation trials as precision medicine approaches advance
- Gene therapy programs (AAV-based) entering Phase 1/2 first-in-human studies
- Non-motor symptom trials (cognitive decline, depression, autonomic dysfunction)
- Status changes: trials beginning to recruit or advancing from Phase 2 to Phase 3
- Competitive pipeline updates from major CNS-focused sponsors
Get daily Parkinson's disease trial digest
Set your profile once. Receive a clean digest every morning with new PD trials and updates matching your criteria.
Get the Free DigestWhat DataLookout monitors for Parkinson's disease
DataLookout pulls directly from the ClinicalTrials.gov API every day. For a Parkinson's watch profile, you can configure:
- Condition keywords: "Parkinson's disease", "Parkinson disease", "PD", "LRRK2", "GBA1", "alpha-synuclein", "synucleinopathy", "Lewy body"
- Phase filter: Early Phase 1, Phase 2, Phase 2/3, or pivotal Phase 3 trials only
- Sponsor filter: Industry-sponsored programs (competitive intelligence) or all sponsors including NIH, Michael J. Fox Foundation-funded academic studies
- Status filter: Recruiting only, all active studies, or any status including completed/terminated
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Parkinson's Disease trial on your watchlist. Each change is classified as critical, notable, or minor, so a trial flipping from recruiting to suspended does not read the same as a contact-details edit.
Who uses Parkinson's disease trial monitoring
Neurology pharma business development teams
BD teams at CNS-focused pharmaceutical companies track the emerging Parkinson's pipeline to identify licensing, co-development, and acquisition opportunities. A new Phase 1 alpha-synuclein antibody program from a well-capitalized biotech is material intelligence. Knowing the day it's registered — and being able to track its progression — gives BD teams a competitive edge.
Biotech investors and CNS-focused analysts
Investors covering neurology track clinical trial registrations as leading indicators of pipeline advancement. A Phase 3 initiation in a validated target like LRRK2 inhibition can precede a major financing event or partnership announcement by many months.
Clinical research organizations (CROs) with neurology practices
CROs specializing in neurology track new PD trial registrations to identify programs entering the active clinical phase — sponsors who will need site selection, patient recruitment, and data management support for complex CNS trials.
Patient advocacy organizations and foundations
Organizations like the Parkinson's Foundation and Michael J. Fox Foundation track new recruiting trials to connect patients with relevant clinical trial opportunities and monitor the overall health of the research pipeline.
Ready to automate your Parkinson's disease trial monitoring?
free plan — no credit card required.
Start FreeFrequently asked questions
How current is the Parkinson's disease trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated continuously as sponsors register new studies or submit protocol amendments.
Can I track disease-modifying and symptomatic trials separately?
Yes. On the Pro plan ($149/month), you can create unlimited watchlists. For example: one profile for disease-modifying programs (alpha-synuclein, LRRK2, GBA1 keywords), another for symptomatic relief trials, and a third for gene/cell therapy first-in-human studies.
Does DataLookout cover atypical parkinsonism — PSP, MSA, LBD?
Yes — you can configure keywords for progressive supranuclear palsy (PSP), multiple system atrophy (MSA), Lewy body dementia (LBD), and corticobasal syndrome. These related synucleinopathies are all registered on ClinicalTrials.gov and searchable within the same platform.
Does DataLookout cover international Parkinson's disease trials?
ClinicalTrials.gov includes internationally conducted trials when the sponsor registers them. Major industry-sponsored Phase 2/3 PD trials, which frequently include European and global sites, are generally registered and included.
1091 active trials, 638 recruiting.
Industry sponsors run 156 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 106.
| Top industry sponsor | Active trials |
|---|---|
| InSightec | 10 |
| AbbVie | 9 |
| iRegene Therapeutics Co., Ltd. | 6 |
| Roche / Genentech | 4 |
| AskBio Inc | 3 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001)… NCT06482268 | Recruiting | Primary completion pushed: 2025-02-28 → 2027-12-28 | 2026-08-18 |
| The Effect of Eye Exercises in Parkinson's Disease NCT07525973 | Enrolling by Invitation | Completion pushed: 2026-09-01 → 2026-10 | 2026-09-16 |
| Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease NCT06422208 | Enrolling by Invitation | Completion pushed: 2027-12 → 2028-12 | 2026-09-16 |
| Neurofeedback Using Implanted Deep Brain Stimulation Electrodes NCT05101161 | Recruiting | Completion pushed: 2026-09-23 → 2028-09-23 | 2026-09-15 |
| Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme NCT05266872 | Recruiting | Completion pushed: 2025-12-31 → 2027-12-31 | 2026-09-15 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.